Drug intelligence / Profile preview

altSonflex1-2-3

Development stage: Phase 2
Lead developer: Bharat Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**altSonflex1-2-3** is an investigational multicomponent **Shigella vaccine** developed by GSK for prevention of shigellosis. The vaccine is designed to generate protective immune responses against *Shigella sonnei* and *Shigella flexneri* serotypes 1b, 2a, and 3a. It has been evaluated in a staged first-in-human Phase 1/2 age-de-escalation program in European and African adults, African children, and African infants, followed by Phase 2 assessment of an alternative two-dose infant schedule and long-term immunogenicity follow-up.

Brand names: altSonflex1-2-3altSonflex-1-2-3altSonflex 1-2-3
Other names: GVGH altSonflex1-2-3 vaccine

Targets

S. flexneri 3a O-antigen (Shigella flexneri serotype 3a O-antigen)

Beyond the preview

Go deeper on altSonflex1-2-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on altSonflex1-2-3.

Explore the full profile